Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging

Ventripoint Diagnostics is expanding subscription access to its FDA-cleared AI cardiac imaging platform, VMS+ 4.0, which provides 3D heart ultrasound analysis. The subscription model aims to lower the barrier for hospitals to adopt advanced cardiac imaging without upfront capital purchases.

This Wire brief sits within Fusion42's coverage of Medtech.